Payment overview · 2025
General Payments
$606.87
34 reported records · 12 companies
Healthcare provider profile · identity verified
Samir Rahbe, MD
Allopathic & Osteopathic Physicians|Internal Medicine · CLEVELAND, TN · NPI 1073665642
Verified facts
What the public records show
CMS Open Payments records show Samir Rahbe, MD received $606.87 in general payments during 2025 across 34 reported records.
Otsuka America Pharmaceutical, Inc. accounted for 31.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Brilinta, Rexulti, Verquvo.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Farxiga by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Rexulti by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VERQUVO as an associated drug or biological on 38060 records involving 12268 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Verquvo by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 390 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Nurtec Odt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $192.97 | 31.8% | 12 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $80.29 | 13.2% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $61.57 | 10.2% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $54.72 | 9.0% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $50.57 | 8.3% | 3 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $39.34 | 6.5% | 2 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $36.69 | 6.0% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $19.67 | 3.2% | 1 | 2025 |
| Intra-Sana Laboratories | Unresolved — no canonical attribution shown | $19.30 | 3.2% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$17.71 | 2.9% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $17.13 | 2.8% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $16.91 | 2.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $606.87 | 34 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $273.26 | 15 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $54.72 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $54.72 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $50.57 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $46.70 | 3 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $39.34 | 2 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $36.69 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $19.96 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $19.67 | 1 | 2025 |
Source payment records
|
|||||
| GLYCATE Normalized: glycate |
Drug | Intra-Sana Laboratories | $19.30 | 1 | 2025 |
Source payment records
|
|||||
| RELTONE 200 MG Normalized: reltone 200 mg |
Drug | Intra-Sana Laboratories | $19.30 | 1 | 2025 |
Source payment records
|
|||||
| RELTONE 400 MG Normalized: reltone 400 mg |
Drug | Intra-Sana Laboratories | $19.30 | 1 | 2025 |
Source payment records
|
|||||
| KYPHON EXPRESS II KYPHOPAK TRAY Normalized: kyphon express ii kyphopak tray |
Device | Medtronic, Inc. | $17.71 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $17.13 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $16.91 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $16.91 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $16.91 | 1 | 2025 |
Source payment records
|
|||||
| BRILINTA Normalized: brilinta |
Drug | AstraZeneca Pharmaceuticals LP | $14.87 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| BRILINTA brilinta |
2025 | Brilinta | 2024 | 39 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 58 | exact normalized | Medicare Part D |
| VERQUVO verquvo |
2025 | Verquvo | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
61 | 15 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
58 | 13 |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | VERQUVO open payments reported associated product |
CMS Open Payments — General Payments 38060 supporting records · 12268 recipient NPIs · example record 1237992208 |
Verquvo · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
58 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
390 | 65 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 740 | 175 |
| Levothyroxine Sodium | Levothyroxine Sodium | 724 | 138 |
| Amlodipine Besylate | Amlodipine Besylate | 611 | 149 |
| Furosemide | Furosemide | 540 | 94 |
| Alprazolam | Alprazolam | 456 | 73 |
| Lisinopril | Lisinopril | 415 | 105 |
| Tamsulosin Hcl | Tamsulosin Hcl | 403 | 80 |
| Omeprazole | Omeprazole | 396 | 102 |
| Eliquis | Apixaban | 390 | 65 |
| Metformin Hcl | Metformin Hcl | 371 | 83 |
| Hydrochlorothiazide | Hydrochlorothiazide | 354 | 88 |
| Metoprolol Tartrate | Metoprolol Tartrate | 344 | 79 |
| Xarelto | Rivaroxaban | 329 | 39 |
| Losartan Potassium | Losartan Potassium | 307 | 77 |
| Montelukast Sodium | Montelukast Sodium | 295 | 91 |
| Metoprolol Succinate | Metoprolol Succinate | 289 | 71 |
| Gabapentin | Gabapentin | 272 | 47 |
| Duloxetine Hcl | Duloxetine Hcl | 262 | 52 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 259 | 66 |
| Trazodone Hcl | Trazodone Hcl | 240 | 55 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 231 | 60 |
| Simvastatin | Simvastatin | 225 | 59 |
| Carvedilol | Carvedilol | 220 | 52 |
| Potassium Chloride | Potassium Chloride | 213 | 58 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 204 | 45 |
| Pantoprazole Sodium | Pantoprazole Sodium | 191 | 52 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 189 | 66 |
| Clopidogrel | Clopidogrel Bisulfate | 183 | 55 |
| Ibuprofen | Ibuprofen | 182 | 63 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 151 | 43 |
| Famotidine | Famotidine | 142 | 42 |
| Sertraline Hcl | Sertraline Hcl | 141 | 32 |
| Terazosin Hcl | Terazosin Hcl | 130 | 27 |
| Zolpidem Tartrate | Zolpidem Tartrate | 127 | 19 |
| Ozempic | Semaglutide | 126 | 26 |
| Quetiapine Fumarate | Quetiapine Fumarate | 121 | 26 |
| Ropinirole Hcl | Ropinirole Hcl | 119 | 23 |
| Buspirone Hcl | Buspirone Hcl | 115 | 25 |
| Tramadol Hcl | Tramadol Hcl | 114 | 34 |
| Mirtazapine | Mirtazapine | 108 | 32 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 107 | 82 |
| Glimepiride | Glimepiride | 107 | 28 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 107 | 19 |
| Levetiracetam | Levetiracetam | 105 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 104 | 26 |
| Fluoxetine Hcl | Fluoxetine Hcl | 103 | 23 |
| Memantine Hcl | Memantine Hcl | 100 | 22 |
| Clonidine Hcl | Clonidine Hcl | 99 | 30 |
| Allopurinol | Allopurinol | 97 | 30 |
| Cefdinir | Cefdinir | 97 | 74 |
| Escitalopram Oxalate | Escitalopram Oxalate | 96 | 21 |
| Alendronate Sodium | Alendronate Sodium | 90 | 24 |
| Prednisone | Prednisone | 89 | 64 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 88 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 84 | 34 |
| Myrbetriq | Mirabegron | 83 | suppressed |
| Temazepam | Temazepam | 82 | 15 |
| Tizanidine Hcl | Tizanidine Hcl | 82 | 17 |
| Ondansetron Odt | Ondansetron | 81 | 25 |
| Donepezil Hcl | Donepezil Hcl | 78 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 77 | 20 |
| Spironolactone | Spironolactone | 76 | 23 |
| Mounjaro | Tirzepatide | 75 | 15 |
| Baclofen | Baclofen | 74 | 22 |
| Solifenacin Succinate | Solifenacin Succinate | 74 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 73 | 16 |
| Lovastatin | Lovastatin | 72 | 16 |
| Meloxicam | Meloxicam | 68 | 18 |
| Topiramate | Topiramate | 67 | 12 |
| Lactulose | Lactulose | 66 | suppressed |
| Jardiance | Empagliflozin | 65 | 12 |
| Synthroid | Levothyroxine Sodium | 65 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 61 | 15 |
| Finasteride | Finasteride | 61 | 16 |
| Bumetanide | Bumetanide | 60 | 19 |
| Ezetimibe | Ezetimibe | 59 | 19 |
| Ondansetron Hcl | Ondansetron Hcl | 58 | 29 |
| Rexulti | Brexpiprazole | 58 | 13 |
| Entresto | Sacubitril/Valsartan | 57 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 57 | 41 |
| Trulicity | Dulaglutide | 56 | 13 |
| Linzess | Linaclotide | 55 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 55 | 16 |
| Clonazepam | Clonazepam | 53 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 53 | 15 |
| Valacyclovir | Valacyclovir Hcl | 53 | 19 |
| Fluconazole | Fluconazole | 52 | 36 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 51 | 14 |
| Pregabalin | Pregabalin | 50 | suppressed |
| Levofloxacin | Levofloxacin | 48 | 30 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 47 | 18 |
| Diclofenac Sodium | Diclofenac Sodium | 45 | 11 |
| Metformin Hcl Er | Metformin Hcl | 43 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 42 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 42 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 41 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 40 | suppressed |
| Brilinta | Ticagrelor | 39 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 39 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 38 | 12 |
| Midodrine Hcl | Midodrine Hcl | 38 | suppressed |
| Nifedipine Er | Nifedipine | 38 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 36 | suppressed |
| Gemfibrozil | Gemfibrozil | 35 | suppressed |
| Mupirocin | Mupirocin | 35 | 23 |
| Januvia | Sitagliptin Phosphate | 34 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 34 | suppressed |
| Primidone | Primidone | 34 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 33 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 33 | 14 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 33 | suppressed |
| Insulin Lispro | Insulin Lispro | 32 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 32 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Novolog Flexpen | Insulin Aspart | 31 | 11 |
| Sucralfate | Sucralfate | 31 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 31 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 29 | suppressed |
| Azithromycin | Azithromycin | 29 | 20 |
| Propranolol Hcl | Propranolol Hcl | 29 | suppressed |
| Xifaxan | Rifaximin | 29 | suppressed |
| Atenolol | Atenolol | 28 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 28 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 27 | suppressed |
| Lorazepam | Lorazepam | 27 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 27 | 13 |
| Nystatin | Nystatin | 27 | 17 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 26 | suppressed |
| Fosfomycin Tromethamine | Fosfomycin Tromethamine | 24 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 24 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 24 | suppressed |
| Premarin | Estrogens, Conjugated | 24 | suppressed |
| Acyclovir | Acyclovir | 23 | suppressed |
| Torsemide | Torsemide | 23 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 23 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 22 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 22 | suppressed |
| Lidocaine | Lidocaine | 22 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 22 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 21 | 18 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 21 | suppressed |
| Digoxin | Digoxin | 20 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 20 | suppressed |
| Estradiol | Estradiol | 20 | suppressed |
| Folic Acid | Folic Acid | 20 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 20 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 20 | 17 |
| Prazosin Hcl | Prazosin Hcl | 20 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 19 | 14 |
| Dicyclomine Hcl | Dicyclomine Hcl | 19 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 18 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 18 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 18 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 18 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 18 | suppressed |
| Verquvo | Vericiguat | 18 | suppressed |
| Benzonatate | Benzonatate | 17 | 15 |
| Glipizide | Glipizide | 17 | suppressed |
| Methocarbamol | Methocarbamol | 17 | suppressed |
| Olanzapine | Olanzapine | 17 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 17 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Cephalexin | Cephalexin | 16 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 16 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 16 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 15 | suppressed |
| Amoxicillin | Amoxicillin | 15 | 11 |
| Diazepam | Diazepam | 15 | suppressed |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Levemir | Insulin Detemir | 15 | suppressed |
| Lubiprostone | Lubiprostone | 15 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 15 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 15 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | 12 |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Novolog | Insulin Aspart | 14 | suppressed |
| Tiotropium Bromide | Tiotropium Bromide | 14 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 14 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 13 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Eszopiclone | Eszopiclone | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Lacosamide | Lacosamide | 13 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 13 | suppressed |
| Methimazole | Methimazole | 13 | suppressed |
| Rybelsus | Semaglutide | 13 | suppressed |
| Budesonide | Budesonide | 12 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 12 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 12 | suppressed |
| Fingolimod | Fingolimod Hcl | 12 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | 12 |
| Verapamil Er Pm | Verapamil Hcl | 12 | suppressed |
| Carbamazepine | Carbamazepine | 11 | suppressed |
| Celecoxib | Celecoxib | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Praluent Pen | Alirocumab | 11 | suppressed |
| Tresiba | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $606.87 · 34 records | Otsuka America Pharmaceutical, Inc. | ABRYSVO, AIRSUPRA, BRILINTA, CAPLYTA, CAPVAXIVE, COMIRNATY, GEMTESA, GLYCATE, GVOKE HYPOPEN, KYPHON EXPRESS II KYPHOPAK TRAY, Kerendia, OTEZLA, PREVNAR 20, RELTONE 200 MG, RELTONE 400 MG, REPATHA, REXULTI, VERQUVO | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Brilinta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error